Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 17, 2006 02:22 ET | Source: Crucell N.V.

Crucell and DSM Biologics Announce Second PER.C6 Licensing Agreement With MorphoSys

LEIDEN, Netherlands and SITTARD, Netherlands, Aug. 17, 2006 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Nasdaq:CRXL) (Swiss Exchange:CRX) and technology partner DSM Biologics today...
August 15, 2006 08:24 ET | Source: Crucell N.V.

Crucell to Release Q2 2006 Earnings on Tuesday, August 29, 2006

LEIDEN, Netherlands, Aug. 15, 2006 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Nasdaq:CRXL) (Swiss Exchange:CRX) today announced that it will release its financial results for the second...
November 23, 2005 02:06 ET | Source: Crucell N.V.

Crucell Announces PER.C6 Licensing Agreement with Tibotec

LEIDEN, Netherlands, Nov. 23, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has signed a PER.C6(r) license agreement with...
November 02, 2005 02:12 ET | Source: Crucell N.V.

Crucell Teams up with ACE BioSciences and Harvard to Accelerate Bacterial Antibody Program

LEIDEN, Netherlands, Nov. 02, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has licensed bacterial antigens from ACE BioSciences...
November 01, 2005 08:20 ET | Source: Crucell N.V.

Crucell to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference, November 8

LEIDEN, Netherlands, Nov. 01, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) today announced that its Chief Financial Officer, Leonard Kruimer CPA, will...
October 20, 2005 02:10 ET | Source: Crucell N.V.

Crucell N.V: Tokyo Infectious Diseases Forum Highlights Strategies to Combat Flu and Other Pandemics

Vaccines and therapies, including antibody preparations, have to be developed in short timeframes; Global cooperation essential, as with SARS TOKYO,...
October 19, 2005 02:12 ET | Source: Crucell N.V.

Crucell and DSM Announce PER.C6 Licensing Agreement with IQ Corporation for Production of Monoclonal Antibodies against Anthrax

LEIDEN and SITTARD, Netherlands, Oct. 19, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today...
October 17, 2005 08:08 ET | Source: Crucell N.V.

Crucell Announces Third Quarter 2005 Results

LEIDEN, Netherlands, Oct. 17, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) today announced its financial results for the third quarter and for the nine...
October 10, 2005 02:17 ET | Source: Crucell N.V.

Crucell N.V.: Merck and Co., Inc. Exercises Option on PER.C6 License for Adenovirus-based Vaccine Against Hepatitis C

LEIDEN, Netherlands, Oct. 10, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that Merck & Co., Inc. (NYSE:MRK) has exercised its option...
October 03, 2005 08:36 ET | Source: Crucell N.V.

Crucell to Release Third Quarter Results on Monday, October 17

LEIDEN, Netherlands, Oct. 3, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Nasdaq:CRXL) (Euronext:CRXL) today announced that it will release its financial results for the third...

Next Page keyboard_arrow_right